Creative Planning’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-3,591
| Closed | -$211K | – | 3042 |
|
|
2023
Q4 | $211K | Buy |
3,591
+3,441
| +2,294% | +$193K | ﹤0.01% | 2386 |
|
|
2023
Q3 | $6.53K | Buy |
+150
| New | +$5.36K | ﹤0.01% | 2690 |
|
|
2022
Q1 | – | Sell |
-1,554
| Closed | -$228K | – | 2462 |
|
|
2021
Q4 | $228K | Sell |
1,554
-7
| -0.4% | -$1.09K | ﹤0.01% | 1796 |
|
|
2021
Q3 | $276K | Buy |
1,561
+7
| +0.5% | +$1.13K | ﹤0.01% | 1645 |
|
|
2021
Q2 | $251K | Sell |
1,554
-2,000
| -56% | -$321K | ﹤0.01% | 1663 |
|
|
2021
Q1 | $609K | Buy |
3,554
+139
| +4% | +$27.5K | ﹤0.01% | 1297 |
|
|
2020
Q4 | $750K | Hold |
3,415
| – | – | ﹤0.01% | 1094 |
|
|
2020
Q3 | $567K | Buy |
3,415
+15
| +0.4% | +$2.05K | ﹤0.01% | 1074 |
|
|
2020
Q2 | $388K | Buy |
3,400
+250
| +8% | +$24.2K | ﹤0.01% | 1165 |
|
|
2020
Q1 | $242K | Sell |
3,150
-3,780
| -55% | -$339K | ﹤0.01% | 1288 |
|
|
2019
Q4 | $893K | Buy |
6,930
+3,780
| +120% | +$365K | ﹤0.01% | 838 |
|
|
2019
Q3 | $245K | Hold |
3,150
| – | – | ﹤0.01% | 1486 |
|
|
2019
Q2 | $324K | Hold |
3,150
| – | – | ﹤0.01% | 1322 |
|
|
2019
Q1 | $231K | Buy |
+3,150
| New | +$214K | ﹤0.01% | 1492 |
|
|
2015
Q1 | – | Sell |
-258
| Closed | -$5K | – | 4452 |
|
|
2014
Q4 | $5K | Buy |
+258
| New | +$4.35K | ﹤0.01% | 3520 |
|
Other funds holding MRTX
Creative Planning's MRTX Position: Q1 2024 in Review
Creative Planning sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 3,591 shares — an estimated $211K sold.
Creative Planning first reported a position in MRTX in Q4 2014 and held it in 15 quarters. The position peaked at $893K in Q4 2019. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.
- Creative Planning reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Creative Planning sold 3,591 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $211K.
- Creative Planning first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2014 and held it in 15 quarters.
- Creative Planning's Mirati Therapeutics, Inc. Common Stock position peaked at $893K in Q4 2019.
- 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Creative Planning's 13F filing for Q1 2024, filed 13 May 2024.